The Role of Novel Methylphenidate Formulations in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD)
- Release date: September 15, 2025
- Expiration date: September 15, 2026
- Estimated time to complete activity: 1.0 hour
- For any questions regarding this activity, please contact MER (www.cmepartner.org)
- MER Privacy Policy
- This activity is jointly provided by Medical Education Resources and MedLearning Inc.
- This activity is supported by an educational grant from Collegium Pharmaceutical.
Please scroll down and click on "Presentation" to view the video
Target Audience
This activity has been designed to meet the educational needs of physicians, nurses, nurse practitioners, and physician assistants involved in the care of patients with ADHD.
Statement of Need/Program Overview
This content will provide practitioners with information on the many formulations of methylphenidate (MPH) to help them in decision-making strategies for their patients with ADHD.
Educational Objectives
After completing this activity, the participant should be better able to:
- Discuss the history, epidemiology and underpinnings associated with ADHD
- Review the treatment options available to manage ADHD
- Examine the different isomers of methylphenidate (MPH) utilized in the treatment of ADHD
- Compare and contrast the available FDA-approved novel formulations of MPH
- Review the possible side effects associated with MPH
Faculty

Medical Director, Rochester Center for Behavioral Medicine, Rochester Hills, MI
Chief Medical Officer, MedaData, LLC
Associate Clinical Professor of Psychiatry, Wayne State School of Medicine, Detroi, MI
Program Agenda
- ADHD Overview
- Treatment Options
- Methylphenidate Overview
-
Novel Methylphenidate Formulations
- Azstarys® (serdexmethylphenidate and dexmethylphenidate capsules)
- Cotempla XR-ODT® (methylphenidate extended-release orally disintegrating tablets)
- Daytrana® (methylphenidate transdermal system)
- Jornay PM® (methylphenidate HCl, extended-release capsules)
- QuilliChew ER® (methylphenidate HCl, extended-release chewable tablets)
- Quillivant XR® (methylphenidate HCl, extended-release oral suspension)
- Methylin Chewable and Methylin oral solution (Methylphenidate HCl) generic
- Relexxii® (methylphenidate HCl, extended-release tablets)
- Safety Overview
- Concluding Thoughts

In support of improving patient care, this activity has been planned and implemented by Medical Education Resources (MER) and MedLearning Inc. MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Credit
Medical Education Resources designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Credit
Medical Education Resources designates this enduring material for a maximum of 1.0 ANCC nursing contact hours.
Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299, for 1.0 contact hours.
Disclosure of Relevant Financial Relationships
Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, MER identifies all financial relationships with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Reported relevant financial relationships are mitigated by MER to ensure that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing learners with high-quality CE activities that promote improvements or quality in health care and not the business interest of an ineligible company.
The authors reported the following financial relationships with ineligible companies whose products or services may be mentioned in this activity:
Name of Faculty |
Reported Financial Relationship |
Joel Young, MD |
Speakers Bureau/Advisory Board: Axsome Therapeutics, Corium Pharma, Ironshore Pharmaceuticals, Janssen Pharmaceuticals, Noven Pharmaceuticals, Otsuka Pharmaceuticals, Supernus Pharmaceuticals, Tris Pharma |
Grants/Research Support: Axsome Therapeutics, Collegium, Janssen Pharmaceuticals, Jazz Pharmaceuticals, Lumos Pharma, Supernus Pharmaceuticals, Tris Pharma |
The content managers reported the following financial relationships with ineligible companies whose products or services may be mentioned in this activity:
Name of Content Manager |
Reported Financial Relationship |
Planners at MedLearning Inc. |
No relevant financial relationships to disclose. |
Planners at Medical Education Resources |
No relevant financial relationships to disclose |
Method of Participation
There are no fees for participating in and receiving credit for this activity. During the period September 2025 through September 2026, participants must 1) read the learning objectives and faculty disclosures, 2) study the educational activity, 3) complete the posttest by recording the best answer to each question, and 4) complete the evaluation form.
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better. Statements of credit will be issued [provide a description of when certificates will be issued and how].
Media
Internet
Disclaimer
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, MedLearning Inc., and/or Collegium Pharmaceutical. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.
Fee Information
There is no fee for this educational activity.
MER Privacy Policy [May include a link to our website – http://cmepartner.org/privacy]
Medical Education Resources and MedLearning Inc. maintain high standards for the protection of privacy over the Internet. The purpose of this statement is to explain what information we obtain, how it is used, and how visitors can restrict its use or disclosure.
The only information MER obtains is information supplied voluntarily by the visitor.
We do not sell or disclose individually identifiable information obtained online unless it is required by law or disclosure is necessary to protect the safety of customers, employees, or property.
We use the information to grade your posttest and to issue a certificate of completion of the activity. If we use a third-party company to grade your posttest and issue certificates of completion, we will give the information to that company for that purpose only.
For each activity that you take, you must complete an evaluation questionnaire. That questionnaire may ask if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
We may use the information to invite you to participate in other activities that we may offer.
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, MER will not share the names or contact information of learners with any ineligible company or its agents without the explicit consent of the individual learner.
Medical Education Resources is committed to safeguarding customer privacy, and we require our employees to protect the privacy of information about our customers. Should you wish to delete your information from our files or discuss our privacy policy, please contact us.